trend
Unilever bets on GLP-1 and AI to blur beauty and wellness
Unilever's Wellbeing division sees GLP-1 drugs and AI-powered health data driving a convergence of beauty and wellness. They're banking on consumers seeking products that address internal biology, like metabolism and skin health, which I get. This isn't just about what's on your face; it's what's happening underneath.
Unilever's Wellbeing division sees GLP-1 drugs and AI-powered health data driving a convergence of beauty and wellness. They're banking on consumers seeking products that address internal biology, like metabolism and skin health, which I get. This isn't just about what's on your face; it's what's happening underneath.
The architecture take
Unilever calling out GLP-1s and AI as the future of beauty and wellness isn't just marketing hype; it's a solid read on where the money's going. If someone's on a GLP-1 drug, their skin and hair can change fast due to rapid weight loss and shifts in nutrition. They'll need specific products to manage that. AI, meanwhile, means more personalized data about blood sugar, hormones, and inflammation becoming accessible. The old 'anti-aging' pitch loses its juice when people want to optimize their actual metabolic function. The play isn't selling a dream anymore; it's selling solutions for what happens when your body chemistry shifts. I mean, if you're dropping 50 pounds, you're not worrying about a fine line; you're worried about texture and elasticity. Watch for the big brands to pivot hard to 'bio-adaptive' products that claim to work with your internal state, not just cover it up.